194 related articles for article (PubMed ID: 12641616)
1. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
McNamara C; Grigg A; Szer J; Roberts A; Campbell L; Hoyt R; Lynch K; Juneja S
Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
[TBL] [Abstract][Full Text] [Related]
2. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
[TBL] [Abstract][Full Text] [Related]
3. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
5. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
7. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
8. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
Hasserjian RP; Boecklin F; Parker S; Chase A; Dhar S; Zaiac M; Olavarria E; Lampert I; Henry K; Apperley JF; Goldman JM
Am J Clin Pathol; 2002 Mar; 117(3):360-7. PubMed ID: 11888075
[TBL] [Abstract][Full Text] [Related]
9. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate].
Chen ZC; You Y; Zhu XM; Li QB; Li WM; Zou P
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):1003-6. PubMed ID: 18478917
[TBL] [Abstract][Full Text] [Related]
10. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Xu Y; Wahner AE; Nguyen PL
Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cojbasić I; Macukanović-Golubović L
Srp Arh Celok Lek; 2010; 138(5-6):305-8. PubMed ID: 20607973
[TBL] [Abstract][Full Text] [Related]
12. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
Cojbasić I; Macukanović-Golubović L
Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
[TBL] [Abstract][Full Text] [Related]
13. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
14. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
15. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
[TBL] [Abstract][Full Text] [Related]
16. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
17. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
18. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
Thiele J; Kvasnicka HM; Varus E; Ollig E; Schmitt-Graeff A; Staib P; Griesshammer M
Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
20. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]